Previous 10 | Next 10 |
Gainers: Nutriband (NTRBW) +84%, Nutriband (OTCQB:NTRB) +38%, Inhibrx (NASDAQ:INBX) +29%, Titan Pharmaceuticals (NASDAQ:TTNP) +14%, Quanterix (NASDAQ:QTRX) +17%. Losers: Organogenesis (NASDAQ:ORGO) -17%, Trevi Therapeutics (NASDAQ:TRVI) -11%,&...
CureVac (NASDAQ:CVAC) -14% after withdrawing first COVID-19 vaccine to focus on new jab with GSK Enzo Biochem (NYSE:ENZ) -9% on FQ4 earnings release Camber Energy (NYSE:CEI) -7%. Trevi Therapeutics (NASDAQ:TRVI) -8%. NanoVibronix (NASDAQ:NAOV) -7%. EZFill Holdings (NASDAQ:...
- COVID-19 vaccine efforts to be re-allocated to accelerate the development of second-generation program in collaboration with GSK - First-generation vaccine candidate, CVnCoV, to be withdrawn from regulatory review due to potential overlap with approval timelines for a second-generatio...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, vaccine stocks are once again in focus for investors. However, this time, the news isn’t as good as investors might hope to see. Source: shutterstock.com/PhotobyTawat Indeed, vaccine stocks such as ...
FN Media Group Presents USA News Group News Commentary Vancouver, BC –September 17, 2021 – USA News Group – Using the same technology as their Covid-19 shot, scientists behind the University of Oxford and AstraZeneca PLC (NASDAQ:AZN) are ge...
CureVac right-sizes manufacturing network to adapt to changes in vaccine peak demands Demand reassessed for first-generation COVID-19 vaccine candidate, CVnCoV, currently under regulatory review with EMA Contracts with manufacturing partners WACKER and Celonic terminated; Rentschl...
According to the White House, three-quarters of adults in the U.S. have received at least one dose of a COVID-19 vaccine as of Tuesday - Bloomberg. White House COVID-19 data director Cyrus Shahpar on Tuesday tweeted that the U.S. "just hit 75% of adults with at least one dose!" The CDC report...
Philippe Laffont’s 13F portfolio value increased from $18.24B to $25.52B this quarter. Coatue Management increased Amazon.com, Moderna, Twilio, and Peloton Interactive while decreasing XPeng and dropping Farfetch Limited. The largest three positions are DoorDash, Amazon.com...
According to a new British study, the risk of long COVID drops nearly in half in people receiving two doses of coronavirus vaccine than unvaccinated people infected with virus, source MarketWatch. The study, published in the journal Lancet Infectious Diseases on Wednesday, found that the odds...
In the same way as Moderna and BioNTech, CureVac makes use of mRNA to develop COVID vaccines. However, in contrast to these two illustrious peers which are at commercialization stage, CureVac's first generation vaccine candidate has exhibited a much lower efficiency against infection....
News, Short Squeeze, Breakout and More Instantly...
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent ...
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone pa...
Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more agile organization Prioritization of high-value opportunities in oncology and other selected diseases, leveraging proprietary mRNA tec...